GLOBAL immunology company Argenx has announced the ARTG registration of Vyvgart (efgartigimod alfa) SC pre-filled syringe as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
CIDP is a rare, severe and progressive autoimmune disease affecting around 3,000 Australians.
The drug belongs to a class of medicines known as neonatal Fc receptor (FcRn) inhibitors, which block the FcRn protein in the blood to accelerate the clearance of harmful immunoglobulin G (IgG) autoantibodies believed to play a role in CIDP.
It is the first therapy with a novel mechanism of action to be approved for CIDP patients in more than 30 years, and marks an important step in addressing unmet needs in this patient group.
Vyvgart was also approved for myasthenia gravis (gMG) this year (PD 10 Mar).
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Mar 26
